Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 236

1.

Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Land SR, Wickerham DL, Costantino JP, Ritter MW, Vogel VG, Lee M, Pajon ER, Wade JL 3rd, Dakhil S, Lockhart JB Jr, Wolmark N, Ganz PA.

JAMA. 2006 Jun 21;295(23):2742-51. Epub 2006 Jun 5. Erratum in: JAMA. 2007 Sep 5;298(9):973.

PMID:
16754728
2.

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL 3rd, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N; National Surgical Adjuvant Breast and Bowel Project (NSABP).

JAMA. 2006 Jun 21;295(23):2727-41. Epub 2006 Jun 5. Erratum in: JAMA. 2006 Dec 27;296(24):2926. JAMA. 2007 Sep 5;298(9):973.

PMID:
16754727
3.

Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.

Ganz PA, Cecchini RS, Julian TB, Margolese RG, Costantino JP, Vallow LA, Albain KS, Whitworth PW, Cianfrocca ME, Brufsky AM, Gross HM, Soori GS, Hopkins JO, Fehrenbacher L, Sturtz K, Wozniak TF, Seay TE, Mamounas EP, Wolmark N.

Lancet. 2016 Feb 27;387(10021):857-65. doi: 10.1016/S0140-6736(15)01169-1. Epub 2015 Dec 11.

PMID:
26686960
4.

The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial.

Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Wolmark N.

Clin Breast Cancer. 2002 Jun;3(2):153-9.

PMID:
12123540
5.

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.

Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL 3rd, Robidoux A, Margolese RG, James J, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N; National Surgical Adjuvant Breast and Bowel Project.

Cancer Prev Res (Phila). 2010 Jun;3(6):696-706. doi: 10.1158/1940-6207.CAPR-10-0076. Epub 2010 Apr 19.

6.

From adjuvant therapy to breast cancer prevention: BCPT and STAR.

Dunn BK, Ford LG.

Breast J. 2001 May-Jun;7(3):144-57. Review.

PMID:
11469927
7.

The NSABP Study of Tamoxifen and Raloxifene (STAR) trial.

Vogel VG.

Expert Rev Anticancer Ther. 2009 Jan;9(1):51-60. doi: 10.1586/14737140.9.1.51. Review. Erratum in: Expert Rev Anticancer Ther. 2009 Mar;9(3):388.

8.

Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

Day R, Ganz PA, Costantino JP, Cronin WM, Wickerham DL, Fisher B.

J Clin Oncol. 1999 Sep;17(9):2659-69.

PMID:
10561339
9.

Selective estrogen receptor modulators and aromatase inhibitors for breast cancer chemoprevention.

Vogel VG.

Curr Drug Targets. 2011 Dec;12(13):1874-87. Review.

PMID:
21158712
10.

The STAR (Study of Tamoxifen and Raloxifene) trial in West Virginia.

Jubelirer SJ, Crowell EB Jr.

W V Med J. 2000 Nov-Dec;96(6):602-4.

PMID:
11194089
11.

Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.

Ganz PA, Land SR.

Menopause. 2008 Jul-Aug;15(4 Suppl):797-803. doi: 10.1097/gme.0b013e31817be9af. Review.

PMID:
18596601
12.

Effects of tamoxifen and raloxifene on memory and other cognitive abilities: cognition in the study of tamoxifen and raloxifene.

Legault C, Maki PM, Resnick SM, Coker L, Hogan P, Bevers TB, Shumaker SA.

J Clin Oncol. 2009 Nov 1;27(31):5144-52. doi: 10.1200/JCO.2008.21.0716. Epub 2009 Sep 21.

13.

Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.

Vogel VG, Costantino JP, Wickerham DL, McCaskill-Stevens W, Clarfeld RB, Grant MD, Wolmark N.

J Natl Cancer Inst Monogr. 2010;2010(41):181-6. doi: 10.1093/jncimonographs/lgq041. Review.

PMID:
20956826
14.
15.

A randomised, double-blind trial comparing raloxifene HCl and continuous combined hormone replacement therapy in postmenopausal women: effects on compliance and quality of life.

Voss S, Quail D, Dawson A, Bäckström T, Aguas F, Erenus M, The HS, Bonnar J, De Geyter C, Hunter M, Nickelsen T; Euralox Investigators Group.

BJOG. 2002 Aug;109(8):874-85.

16.

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.

Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW, Stepan JJ, Powles TJ, Morrow M, Costa A, Silfen SL, Walls EL, Schmitt H, Muchmore DB, Jordan VC, Ste-Marie LG.

Breast Cancer Res Treat. 2001 Jan;65(2):125-34. Erratum in: Breast Cancer Res Treat 2001 May;67(2):191.

PMID:
11261828
17.
18.

Raloxifene (Evista) for breast cancer prevention in postmenopausal women.

[No authors listed]

Med Lett Drugs Ther. 2006 May 8;48(1234):37.

PMID:
16685245
19.

Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.

Levine M, Moutquin JM, Walton R, Feightner J; Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.

CMAJ. 2001 Jun 12;164(12):1681-90. Review.

20.

Symptoms and QOL as Predictors of Chemoprevention Adherence in NRG Oncology/NSABP Trial P-1.

Land SR, Walcott FL, Liu Q, Wickerham DL, Costantino JP, Ganz PA.

J Natl Cancer Inst. 2015 Nov 27;108(4). pii: djv365. doi: 10.1093/jnci/djv365. Print 2016 Apr.

PMID:
26615179
Items per page

Supplemental Content

Write to the Help Desk